EQS-Adhoc: Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders' subscription rights
|
EQS-Ad-hoc: Viromed Medical AG / Key word(s): Capital measures / Capital increase Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders' subscription rights Rellingen, October 26, 2026 – With the approval of the Supervisory Board, the Executive Board of Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), resolved today to increase the company’s share capital – excluding shareholders’ subscription rights – from the current EUR 21,250,000 to EUR 21,700,000, an increase of EUR 450,000. This will be achieved by partially utilising Authorised Capital 2025 through the issuance of 450,000 new registered shares with no par value at a placement price of EUR 4.50 each. Initially, the new shares will be subscribed by Small & Mid Cap Investmentbank AG, Munich, and will subsequently be offered to selected investors as part of a private placement. The gross proceeds from the offering, totalling EUR 2 million, are to be used to finance the company’s working capital. Notifying person: Uwe Perbandt, CEO Viromed Medical AG
Contact Viromed E-Mail: kontakt@viromed-medical.de End of Inside Information
26-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Viromed Medical AG |
| Hauptstraße 105 | |
| 25462 Rellingen | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A40ZVN7 |
| WKN: | A40ZVN |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX |
| LEI Code: | 894500XR05MYCVCCR171 |
| EQS News ID: | 2421728 |
| End of Announcement | EQS News Service |
|
|
2421728 26-Oct-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 1,13 | 5,09 | 8,50 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | -0,11 | 4,98 | 2,25 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | 442,93 | 44,25 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | -0,11 | 4,73 | 1,73 | 8,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | 420,44 | 33,95 | 94,12 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | -0,11 | -3,09 | 0,60 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | -274,84 | 11,87 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | -0,11 | -2,84 | 1,13 | 0,00 | |
| Earnings per share8 | 0,00 | 1,23 | -0,01 | -0,01 | -0,15 | 0,03 | -0,01 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Bernd Lenzen
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Viromed Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZVN | DE000A40ZVN7 | AG | 102,42 Mio € | 04.05.2022 | 9F5FMR3F+R3 | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 59,00 | 0,00 | 0,00 | 236,00 | 10,78 | 90,80 | 20,13 |
|
Dividend '2024 in € |
Dividend '2025 in € |
Dividend '2026e in € |
Div.-Yield '2026e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 06.07.2026 | 28.09.2026 | 22.05.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -19,92% | -25,81% | +24,21% | +45,68% | -1,67% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
